CHRS

Innovent’s Avastin® Biosimilar (bevacizumab)

Non-small-cell lung carcinoma (NSCLC)

Phase 3 (BLA Filing)

Exp Date

Late 2020 / Early 2021

Amp Volatility Score

Catalyst Info & Data Links

TITLE: Innovent’s Avastin® Biosimilar (bevacizumab) in NSCLC - BLA Filing


WHAT IS THE CATALYST EVENT?

  • BLA Filing


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • Late 2020/Early 2021


PRIOR DATA/EVENTS

PRESS RELEASE

POSTERS


PRESENTATIONS


PUBLICATIONS


MARKET

  • ~228,820 adults (116,300 men and 112,520 women) in the US will be diagnosed with lung cancer

  • NSCLC is the most common type of lung cancer, accounting for 84% of all lung cancer diagnoses


MECHANISM OF ACTION / RATIONALE

  • Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.


  • source - FDA Label (section 12.1)

Updated by HC

#CHRS, #Innovent, #Avastin, #Biosimilar, #bevacizumab, #NSCLC, #BLA

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon